51
|
Wilkinson-Berka JL, Tan G, Binger KJ, Sutton L, McMaster K, Deliyanti D, Perera G, Campbell DJ, Miller AG. Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia 2011; 54:2724-35. [PMID: 21755314 DOI: 10.1007/s00125-011-2239-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2011] [Accepted: 06/13/2011] [Indexed: 10/18/2022]
Abstract
AIM/HYPOTHESIS We examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy. METHODS Transgenic (mRen-2)27 rats, which overexpress mouse renin and angiotensin in extra-renal tissues, were studied. For diabetic studies, non-diabetic, diabetic (streptozotocin, 55 mg/kg), diabetic + aliskiren (10 mg kg(-1) day(-1), pump), or diabetic + lisinopril (10 mg kg(-1) day(-1), drinking water) rats were evaluated over 16 weeks. For oxygen-induced retinopathy studies, rats were exposed to 80% oxygen (22 h/day) from postnatal days 0 to 11, and then room air from postnatal days 12 to 18. Aliskiren (10 or 30 mg kg(-1) day(-1), pump) or lisinopril (10 mg kg(-1) day(-1), drinking water) was administered during retinopathy development between postnatal days 12 and 18. RESULTS Systolic BP in diabetic (mRen-2)27 rats was reduced with 10 mg kg(-1) day(-1) aliskiren, but only lisinopril normalised systolic blood pressure. In diabetic (mRen-2)27 rats, 10 mg kg(-1) day(-1) aliskiren and lisinopril reduced retinal acellular capillaries and leucostasis to non-diabetic levels. In oxygen-induced retinopathy, neoangiogenesis and retinal inflammation (leucostasis, ED-1 immunolabelling) were partially reduced by 10 mg kg(-1) day(-1) aliskiren and normalised by 30 mg kg(-1) day(-1) aliskiren, whereas lisinopril normalised neoangiogenesis and reduced leucostasis and ED-1 immunolabelling. Aliskiren and lisinopril normalised retinal vascular endothelial growth factor expression; however, only aliskiren reduced intercellular adhesion molecule-1 to control levels. CONCLUSIONS/INTERPRETATION Aliskiren provided similar or greater retinal protection than ACE inhibition and may be a potential treatment for diabetic retinopathy.
Collapse
Affiliation(s)
- J L Wilkinson-Berka
- Department of Immunology, Monash University, Alfred Medical Research and Education Precinct (AMREP), Commercial Road, Melbourne, 3004 Victoria, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
52
|
Zhang W, Yokota H, Xu Z, Narayanan SP, Yancey L, Yoshida A, Marcus DM, Caldwell RW, Caldwell RB, Brooks SE. Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model. Invest Ophthalmol Vis Sci 2011; 52:6384-95. [PMID: 21705685 DOI: 10.1167/iovs.11-7666] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
PURPOSE To investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy. METHODS Hyperoxia treatment (HT, 40%-75% oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative phase of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied. RESULTS Administration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in Müller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes. CONCLUSIONS HT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities.
Collapse
Affiliation(s)
- Wenbo Zhang
- Vascular Biology Center, Georgia Health Sciences University, Augusta, Georgia 30912-2500, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond) 2011; 120:307-19. [PMID: 21488224 DOI: 10.1042/cs20100389] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Angiotensin II type 1 receptor antagonists [ARBs (angiotensin receptor blockers)] are indicated for BP (blood pressure)-lowering, renal protection and cardioprotection in patients unable to tolerate ACEIs (angiotensin-converting enzyme inhibitors). A recent meta-analysis revealed an association between ARBs and tumour development, possibly due to enhancement of angiogenesis. However, published evidence is conflicting on the effects of ARBs on angiogenesis or the expansion of the existing vascular network. ARBs have been shown to exert primarily anti-angiogenic effects in basic science studies of cancer, retinopathy, peripheral artery disease and some models of cardiovascular disease. In animal and cellular models of myocardial infarction and stroke, however, ARB administration has been associated with robust increases in vascular density and improved recovery. The aim of the present review is to examine the angiogenic effects of ARBs in animal and cellular models of relevant disease states, including proposed molecular mechanisms of action of ARBs and the clinical consequences of ARB use.
Collapse
|
54
|
Fletcher EL, Jobling AI, Vessey KA, Luu C, Guymer RH, Baird PN. Animal models of retinal disease. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2011; 100:211-86. [PMID: 21377628 DOI: 10.1016/b978-0-12-384878-9.00006-6] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Diseases of the retina are the leading causes of blindness in the industrialized world. The recognition that animals develop retinal diseases with similar traits to humans has led to not only a dramatic improvement in our understanding of the pathogenesis of retinal disease but also provided a means for testing possible treatment regimes and successful gene therapy trials. With the advent of genetic and molecular biological tools, the association between specific gene mutations and retinal signs has been made. Animals carrying natural mutations usually in one gene now provide well-established models for a host of inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, inherited macular degeneration, and optic nerve diseases. In addition, the development of transgenic technologies has provided a means by which to study the effects of these and novel induced mutations on retinal structure and function. Despite these advances, there is a paucity of suitable animal models for complex diseases, including age-related macular degeneration (AMD) and diabetic retinopathy, largely because these diseases are not caused by single gene defects, but involve complex genetics and/or exacerbation through environmental factors, epigenetic, or other modes of genetic influence. In this review, we outline in detail the available animal models for inherited retinal diseases and how this information has furthered our understanding of retinal diseases. We also examine how transgenic technologies have helped to develop our understanding of the role of isolated genes or pathways in complex diseases like AMD, diabetes, and glaucoma.
Collapse
Affiliation(s)
- Erica L Fletcher
- Department of Anatomy and Cell Biology, The University of Melbourne, Parkville, Victoria, Australia
| | | | | | | | | | | |
Collapse
|
55
|
Vessey K, Wilkinson-Berka J, Fletcher E. Characterization of retinal function and glial cell response in a mouse model of oxygen-induced retinopathy. J Comp Neurol 2010; 519:506-27. [DOI: 10.1002/cne.22530] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
56
|
Scott A, Powner MB, Gandhi P, Clarkin C, Gutmann DH, Johnson RS, Ferrara N, Fruttiger M. Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PLoS One 2010; 5:e11863. [PMID: 20686684 PMCID: PMC2912336 DOI: 10.1371/journal.pone.0011863] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2010] [Accepted: 07/07/2010] [Indexed: 11/23/2022] Open
Abstract
Vascular endothelial growth factor (VEGF) plays a critical role in normal development as well as retinal vasculature disease. During retinal vascularization, VEGF is most strongly expressed by not yet vascularized retinal astrocytes, but also by retinal astrocytes within the developing vascular plexus, suggesting a role for retinal astrocyte-derived VEGF in angiogenesis and vessel network maturation. To test the role of astrocyte-derived VEGF, we used Cre-lox technology in mice to delete VEGF in retinal astrocytes during development. Surprisingly, this only had a minor impact on retinal vasculature development, with only small decreases in plexus spreading, endothelial cell proliferation and survival observed. In contrast, astrocyte VEGF deletion had more pronounced effects on hyperoxia-induced vaso-obliteration and led to the regression of smooth muscle cell-coated radial arteries and veins, which are usually resistant to the vessel-collapsing effects of hyperoxia. These results suggest that VEGF production from retinal astrocytes is relatively dispensable during development, but performs vessel stabilizing functions in the retinal vasculature and might be relevant for retinopathy of prematurity in humans.
Collapse
Affiliation(s)
- Andrew Scott
- UCL Institute of Ophthalmology, University College London, London, United Kingdom
| | - Michael B. Powner
- UCL Institute of Ophthalmology, University College London, London, United Kingdom
| | - Pranita Gandhi
- UCL Institute of Ophthalmology, University College London, London, United Kingdom
| | - Claire Clarkin
- Division of Reproduction and Endocrinology, King's College London, London, United Kingdom
| | - David H. Gutmann
- Department of Neurology, Washington University, St. Louis, Missouri, United States of America
| | - Randall S. Johnson
- University of California San Diego, La Jolla, California, United States of America
| | - Napoleone Ferrara
- Genentech Inc., South San Francisco, California, United States of America
| | - Marcus Fruttiger
- UCL Institute of Ophthalmology, University College London, London, United Kingdom
- * E-mail:
| |
Collapse
|
57
|
Muscle-derived Gr1(dim)CD11b(+) cells enhance neovascularization in an ischemic hind limb mouse model. Blood 2010; 116:1623-6. [PMID: 20516368 DOI: 10.1182/blood-2009-08-237040] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Gr1(+)CD11b(+) cells are characterized as myeloid-derived suppressor cells potentially involved in angiogenesis. We demonstrate that Gr1(+)CD11b(+) cells isolated from ischemic muscle in a hind-limb ischemic C57BL/6 mouse model play a role in vessel formation after ischemic injury. Gr1(dim)CD11b(+) cells, a subpopulation of Gr1(+)CD11b(+) cells, within skeletal muscle were increased in context of ischemia. Strikingly, astrocyte-plexus formed from muscle-derived Gr1(dim)CD11b(+) cells in Matrigel culture, followed by formation of isolectin and von Willebrand Factor-expressing cells, similar to that reported for angiogenesis in retina. When isolated muscle-derived Gr1(dim)CD11b(+) cells were injected into ischemic muscles, recovery of blood flow was significantly enhanced and these cells were incorporated into vessel walls. This suggests that Gr1(dim)CD11b(+) cells are recruited into ischemic regions after ischemia and may be involved in angiogenesis by their capacity to generate vascular cells.
Collapse
|
58
|
Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, Binger KJ, Campbell DJ, Miller AG. RILLKKMPSV Influences the Vasculature, Neurons and Glia, and (Pro)Renin Receptor Expression in the Retina. Hypertension 2010; 55:1454-60. [DOI: 10.1161/hypertensionaha.109.148221] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jennifer L. Wilkinson-Berka
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Ronen Heine
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Genevieve Tan
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Mark E. Cooper
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Kate M. Hatzopoulos
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Erica L. Fletcher
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Katrina J. Binger
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Duncan J. Campbell
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| | - Antonia G. Miller
- From the Department of Immunology (J.L.W.-B., R.H., G.T., K.J.B., A.G.M.), Monash University and the Juvenile Diabetes Research Foundation Danielle Alberti Centre for Diabetic Complications (M.E.C.), Baker International Diabetes Institute Heart and Diabetes Research Institute, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; Department of Anatomy and Cell Biology (K.M.H., E.L.F.), University of Melbourne, Parkville, Victoria, Australia; St Vincent’s Institute of
| |
Collapse
|
59
|
Villarroel M, Ciudin A, Hernández C, Simó R. Neurodegeneration: An early event of diabetic retinopathy. World J Diabetes 2010; 1:57-64. [PMID: 21537428 PMCID: PMC3083883 DOI: 10.4239/wjd.v1.i2.57] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2009] [Revised: 03/03/2010] [Accepted: 03/10/2010] [Indexed: 02/05/2023] Open
Abstract
Diabetic retinopathy (DR) has been classically considered to be a microcirculatory disease of the retina caused by the deleterious metabolic effects of hyperglycemia per se and the metabolic pathways triggered by hyperglycemia. However, retinal neurodegeneration is already present before any microcirculatory abnormalities can be detected in ophthalmoscopic examination. In other words, retinal neurodegeneration is an early event in the pathogenesis of DR which predates and participates in the microcirculatory abnormalities that occur in DR. Therefore, the study of the mechanisms that lead to neurodegeneration will be essential to identify new therapeutic targets in the early stages of DR. Elevated levels of glutamate and the overexpression of the renin- angiotensin-system play an essential role in the neurodegenerative process that occurs in diabetic retina. Among neuroprotective factors, pigment epithelial derived factor, somatostatin and erythropoietin seem to be the most relevant and these will be considered in this review. Nevertheless, it should be noted that the balance between neurotoxic and neuroprotective factors rather than levels of neurotoxic factors alone will determine the presence or absence of retinal neurodegeneration in the diabetic eye. New strategies, based on either the delivery of neuroprotective agents or the blockade of neurotoxic factors, are currently being tested in experimental models and in clinical pilot studies. Whether these novel therapies will eventually supplement or prevent the need for laser photocoagulation or vitrectomy awaits the results of additional clinical research.
Collapse
Affiliation(s)
- Marta Villarroel
- Marta Villarroel, Andreea Ciudin, Cristina Hernández, Rafael Simó, Diabetes and Metabolism Research Unit. Institut de Recerca Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain
| | | | | | | |
Collapse
|
60
|
Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010; 29:284-311. [PMID: 20380890 DOI: 10.1016/j.preteyeres.2010.03.003] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Renin-Angiotensin System is classically recognized for its role in the control of systemic blood pressure. However, the retina is recognized to have all the components necessary for angiotensin II formation, suggestive of a role for Angiotensin II in the retina that is independent of the systemic circulation. The most well described effects of Angiotensin II are on the retinal vasculature, with roles in vasoconstriction and angiogenesis. However, it is now emerging that Angiotensin II has roles in modulation of retinal function, possibly in regulating GABAergic amacrine cells. In addition, Angiotensin II is likely to have effects on glia. Angiotensin II has also been implicated in retinal vascular diseases such as Retinopathy of Prematurity and diabetic retinopathty, and more recently actions in choroidal neovascularizaiton and glaucoma have also emerged. The mechanisms by which Angiotensin II promotes angiogensis in retinal vascular diseases is indicative of the complexity of the RAS and the variety of cell types that it effects. Indeed, these diseases are not purely characterized by direct effects of Angiotensin II on the vasculature. In retinopathy of prematurity, for example, blockade of AT1 receptors prevents pathological angiogenesis, but also promotes revascularization of avascular regions of the retina. The primary site of action of Angiotensin II in this disease may be on retinal glia, rather than the vasculature. Indeed, blockade of AT1 receptors prevents glial loss and promotes the re-establishment of normal vessel growth. Blockade of RAS as a treatment for preventing the incidence and progression of diabetic retinopathy has also emerged based on a series of studies in animal models showing that blockade of the RAS prevents the development of a variety of vascular and neuronal deficits in this disease. Importantly these effects may be independent of actions on systemic blood pressure. This has culminated recently with the completion of several large multi-centre clinical trials that showed that blockade of the RAS may be of benefit in some at risk patients with diabetes. With the emergence of novel compounds targeting different aspects of the RAS even more effective ways of blocking the RAS may be possible in the future.
Collapse
Affiliation(s)
- Erica L Fletcher
- Department of Anatomy and Cell Biology, The University of Melbourne, Parkville 3010, Victoria, Australia.
| | | | | | | | | |
Collapse
|
61
|
Stevenson L, Matesanz N, Colhoun L, Edgar K, Devine A, Gardiner TA, McDonald DM. Reduced nitro-oxidative stress and neural cell death suggests a protective role for microglial cells in TNFalpha-/- mice in ischemic retinopathy. Invest Ophthalmol Vis Sci 2010; 51:3291-9. [PMID: 20107169 DOI: 10.1167/iovs.09-4344] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE Neovascularization occurs in response to tissue ischemia and growth factor stimulation. In ischemic retinopathies, however, new vessels fail to restore the hypoxic tissue; instead, they infiltrate the transparent vitreous. In a model of oxygen-induced retinopathy (OIR), TNFalpha and iNOS, upregulated in response to tissue ischemia, are cytotoxic and inhibit vascular repair. The aim of this study was to investigate the mechanism for this effect. METHODS Wild-type C57/BL6 (WT) and TNFalpha(-/-) mice were subjected to OIR by exposure to 75% oxygen (postnatal days 7-12). The retinas were removed during the hypoxic phase of the model. Retinal cell death was determined by TUNEL staining, and the microglial cells were quantified after Z-series capture with a confocal microscope. In situ peroxynitrite and superoxide were measured by using the fluorescent dyes DCF and DHE. iNOS, nitrotyrosine, and arginase were analyzed by real-time PCR, Western blot analysis, and activity determined by radiolabeled arginine conversion. Astrocyte coverage was examined after GFAP immunostaining. RESULTS The TNFalpha(-/-) animals displayed a significant reduction in TUNEL-positive apoptotic cells in the inner nuclear layer of the avascular retina compared with that in the WT control mice. The reduction coincided with enhanced astrocytic survival and an increase in microglial cells actively engaged in phagocytosing apoptotic debris that displayed low ROS, RNS, and NO production and high arginase activity. CONCLUSIONS Collectively, the results suggest that improved vascular recovery in the absence of TNFalpha is associated with enhanced astrocyte survival and that both phenomena are dependent on preservation of microglial cells that display an anti-inflammatory phenotype during the early ischemic phase of OIR.
Collapse
Affiliation(s)
- Laura Stevenson
- Centre for Vision and Vascular Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
62
|
|
63
|
Downie LE, Hatzopoulos KM, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Kalloniatis M, Fletcher EL. Angiotensin type-1 receptor inhibition is neuroprotective to amacrine cells in a rat model of retinopathy of prematurity. J Comp Neurol 2010; 518:41-63. [DOI: 10.1002/cne.22205] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
64
|
|
65
|
Rojas M, Zhang W, Lee DL, Romero MJ, Nguyen DT, Al-Shabrawey M, Tsai NT, Liou GI, Brands MW, Caldwell RW, Caldwell RB. Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Invest Ophthalmol Vis Sci 2009; 51:1709-18. [PMID: 19834028 DOI: 10.1167/iovs.09-3375] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE The production of proinflammatory cytokines has been shown to play a critical role in a variety of retinal vascular diseases. Angiotensin II and VEGF have been implicated in the initiation of vascular inflammation and retinal vascular disease. However, detailed mechanisms of this process and interactions between inflammatory agonists and angiotensin II in promoting retinopathy are poorly understood. The present study was an investigation of the role of interleukin (IL)-6 in angiotensin II-induced retinopathy. METHODS Rats and IL-6-deficient and wild-type mice were treated with angiotensin II or IL-6, and their retinas were analyzed for leukocyte adhesion or for the expression and localization of VEGF or IL-6. Leukocyte adhesion was assayed by concanavalin A labeling. Vascular density was determined by morphometric analysis. NADPH oxidase activity was assayed by dihydroethidium imaging of superoxide. RESULTS Intravitreal injection of angiotensin II caused increases in IL-6 mRNA and protein and in leukocyte adhesion to the retinal vessels. IL-6 protein was localized to CD11b-positive microglia and macrophage-like cells. Angiotensin II treatment stimulated increases in retinal levels of VEGF expression and NADPH oxidase activity, which were associated with increased surface area and remodeling of the retinal vessels. These effects were blocked by knocking out IL-6. Intravitreal IL-6 directly induced leukocyte adhesion in both wild-type and IL-6-deficient mice. CONCLUSIONS The results indicate that IL-6 expression is essential for angiotensin II-induced increases in retinal VEGF expression, leukostasis, and vascular remodeling. The data suggest a critical role for IL-6 in mediating angiotensin II-induced retinal vascular inflammation and remodeling.
Collapse
|
66
|
Fletcher EL, Downie LE, Hatzopoulos K, Vessey KA, Ward MM, Chow CL, Pianta MJ, Vingrys AJ, Kalloniatis M, Wilkinson-Berka JL. The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol 2009; 120:67-86. [PMID: 19763649 DOI: 10.1007/s10633-009-9193-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2009] [Accepted: 08/17/2009] [Indexed: 12/31/2022]
Abstract
Retinopathy of prematurity is a devastating vascular disease of premature infants. A number of studies indicate that retinal function is affected in this disease. Using the rat model of oxygen-induced retinopathy, it is possible to explore more fully the complex relationship between neuronal, glial and vascular pathology in this condition. This review examines the structural and functional changes that occur in the rat retina following oxygen-induced retinopathy. We highlight that vascular pathology in rats is characterized by aberrant growth of blood vessels into the vitreous at the expense of blood vessel growth into the body of the retina. Moreover, amino acid neurochemistry, a tool for examining neuronal changes in a spatially complete manner reveals widespread changes in amacrine and bipolar cells. In addition, neurochemical anomalies within inner retinal neurons are highly correlated with the absence of retinal vessels. The key cell types that link blood flow with neuronal function are macroglia. Macroglia cells, which in the retina include astrocytes and Müller cells, are affected by oxygen-induced retinopathy. Astrocyte loss occurs in the peripheral retina, while Müller cells show signs of reactive gliosis that is highly localized to regions that are devoid of intraretinal blood vessels. Finally, we propose that treatments, such as blockade of the renin-angiotensin system, that not only targets pathological angiogenesis, but that also promotes re-vascularization of the retina are likely to prove important in the treatment of those with retinopathy of prematurity.
Collapse
Affiliation(s)
- Erica L Fletcher
- Department of Anatomy and Cell Biology, The University of Melbourne, Grattan St., Parkville, VIC 3010, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Downie LE, Vessey K, Miller A, Ward MM, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 2009; 161:195-213. [PMID: 19298848 DOI: 10.1016/j.neuroscience.2009.02.084] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2008] [Revised: 02/27/2009] [Accepted: 02/28/2009] [Indexed: 10/21/2022]
Abstract
The bio-active peptide, angiotensin II (Ang II), has been suggested to exert a neuromodulatory effect on inner retinal neurons. In this study, we examined the distribution of angiotensin receptors (ATRs) in the developing and mature rat retina and optic nerve using immunofluorescence immunocytochemistry. Double-labeling experiments were performed with established markers to identify different retinal cell populations. In adult retinae, ATRs were observed on neurons involved in "ON" pathways of neurotransmission. Angiotensin II type 1 receptors (AT(1)Rs) were expressed by a sub-population of "ON" cone bipolar cells that also labeled for G alpha(0) and islet-1. Extra-neuronal expression of AT(1)Rs was evident on retinal astrocytes, Müller cells and blood vessels. Immunoreactivity for the angiotensin II type 2 receptor (AT(2)R) was observed on conventional and displaced GABAergic amacrine cells. Co-localization studies showed that AT(2)R-expressing amacrine cells constituted at least two separate sub-populations. Cell counts revealed that all wide-field amacrine cells expressing protein kinase C-alpha were also AT(2)R-positive; a further subset of amacrine cells expressing AT(2)Rs and stratifying in sublamina "b" of the inner plexiform layer (IPL) was identified. Developmental expression of AT(1)Rs was dynamic, involving multiple inner neuronal classes. At postnatal day 8 (P8), AT(1)R immunoreactivity was observed on putative ganglion cells. The characteristic bipolar cell labeling observed in adults was not evident until P13. In contrast, AT(2)Rs were detected as early as P2 and localized specifically to amacrine cells from this age onward. These data provide further evidence for the potential role of angiotensin II in the modulation of retinal neurons and glia. The differential pattern of expression of these receptors across these cell types is similar to that observed in the brain and suggests that a similar functional role for Ang II may also exist within the retina.
Collapse
Affiliation(s)
- L E Downie
- Department of Anatomy and Cell Biology, The University of Melbourne, Grattan Street, Parkville 3010, Victoria, Australia 3010
| | | | | | | | | | | | | | | |
Collapse
|